Skip to content
diversity_3Autism (ASD)

Medication Treatment in Autism

No medication treats autism itself — but some help, and a lot, with what comes along with it.

Translated from the Portuguese original. Read the original (Português)

boltIn short

There is no medication that treats the core symptoms of autism: social communication and restricted, repetitive patterns. What medication can do is relieve associated symptoms and co-occurring conditions — severe irritability, hyperactivity, anxiety, depression, insomnia, epilepsy. It comes in after investigating clinical and environmental causes and putting behavioral and educational interventions in place, and it works best together with them — never in their place. The doctor is always the one who prescribes, adjusts, and follows up.

Technical definition

Medication treatment in autism is the use of drugs as part of the care of a person with Autism Spectrum Disorder, always with a defined target: not the diagnosis itself, but specific symptoms (severe irritability, aggression, self-injury, hyperactivity, insomnia) or co-occurring conditions that have their own treatment (ADHD, anxiety disorders, depression, epilepsy). No medication is indicated for the core symptoms of ASD — persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior. The reference guidelines (American Academy of Pediatrics, 2020; NICE CG170) position the drug as an adjuvant: it comes in when behavioral and educational interventions and changes to the environment have not been enough, and it continues alongside them.

What medication reaches — and what it doesn't

This is the distinction that organizes everything else. Autism is a neurodevelopmental condition, not a disease with a single mechanism to be corrected by a pill. That's why NICE is explicit in saying that antipsychotics should not be used to manage the core features of autism — and adds the same recommendation for antidepressants, anticonvulsants, and exclusion diets.

But a lot of what causes an autistic person to suffer is not autism itself: it's the anxiety that keeps them from leaving the house, the insomnia that disrupts the whole family, the irritability crisis that hurts, the inattention that gets in the way of learning. These things do have treatment — and part of it can be medication.

Core symptoms social communication social interaction repetitive behaviors restricted interests routines and sensitivity no medication treats Associated symptoms severe irritability hyperactivity (ADHD) anxiety and depression insomnia epilepsy may respond to medication
The target of medication is never autism itself: it's what comes along with it and causes suffering or risk.

Before medicating, what comes first

When a behavior becomes difficult — screaming, aggression, self-injury —, the right question isn't “which medication?”, but “what is going on?”. The American Academy of Pediatrics describes a stepwise path: investigate what might be behind it, understand the function of the behavior, adjust the environment and interventions, and only then consider medication.

1 Investigate causes 2 Functional assessment 3 Intervention and environment 4 Medication with target
Medication is the fourth step, not the first — and the previous three still apply after it comes in.

The first step covers clinical causes that hurt and go unexplained. A person with limited speech who starts hitting themselves might have a toothache, an ear infection, constipation, reflux, a migraine, or menstrual cramps. Poor sleep and unnoticed seizures also change behavior. Investigating this isn't bureaucracy: it's the step that most prevents unnecessary medication.

The second and third steps cover what the behavior produces and what the environment demands. It's worth asking:

  • what has changed — routine, school, caregiver, noise, temperature, crowding?
  • does the person have some way to ask for and refuse things that works, or is screaming the only thing that's heard?
  • is the demand above what they can currently manage?
  • is the behavior followed by attention, escape from a task, or access to something?

This is what functional analysis is about, and it's why the plan for challenging behaviors comes before the prescription. When these steps have been followed and the behavior remains severe, disabling, or dangerous, that's when medication is discussed — with a written target and a date to reassess.

What the evidence shows, target by target

Each target has its own research history. Choose one:

Irritability, aggression, and self-injury

This is the target with the strongest evidence and the only one with specific regulatory approval in the United States and Brazil. Two second-generation antipsychotics, risperidone and aripiprazole, were approved by the U.S. agency (FDA) for “irritability associated with autistic disorder” in 2006 and 2009, in children and adolescents. In Brazil, risperidone carries this indication in the package insert approved by Anvisa. A Cochrane review on aripiprazole concluded that, in the short term, it improves irritability, hyperactivity, stereotypies, and inappropriate speech compared with placebo — and that the adverse effects (weight gain, sedation, excessive salivation, and tremor) require careful weighing. Note what this does not mean: reducing irritability is not treating autism, and the approval is for a symptom, not for the condition.

Hyperactivity and inattention

ADHD is one of the conditions that most commonly co-occurs with autism, and since the DSM-5 it can be diagnosed alongside it. The reference trial is the one from the RUPP network (2005), which tested methylphenidate against placebo in children with spectrum disorders and hyperactivity: the medication was superior to placebo, but only about half of the children responded — a smaller proportion than observed in children with ADHD without autism — and adverse effects were more frequent, especially at higher doses. The practical takeaway is realistic expectations and close monitoring, not refusal. Other non-stimulant medications are also used for this target, always by medical decision.

Anxiety and depression

There's a mix-up here worth untangling. A Cochrane review on SSRI antidepressants in autism found no evidence of effect in children — with signs of harm — and considered the evidence in adults limited and not yet robust. But that review answers a specific question: using SSRIs to treat autism, targeting repetitive behaviors. It does not say that an autistic person with a diagnosed anxiety disorder or depression should go untreated: in that case, the care proper to that condition applies, with evidence-based psychotherapy and, when the doctor indicates it, medication — with extra attention, because autistic people may be more sensitive to adverse effects and have more difficulty reporting how they're feeling.

Sleep difficulties

Sleeping poorly is very common in autism and makes everything else worse — mood, learning, behavior, the whole family's night. The first treatment is behavioral: predictable schedules, a wind-down routine, a dark and quiet environment, screens away from the end of the day. When that isn't enough, melatonin is the most studied option: meta-analyses show that autistic children fall asleep faster and sleep longer than with placebo, although no significant effect is observed on nighttime awakenings — falling asleep faster and sleeping longer doesn't mean the child stops waking up overnight. In Europe, an extended-release pediatric formulation has been registered since 2018 specifically for insomnia in children and adolescents with ASD. In Brazil, the situation is different: there is no melatonin registered as a medication, and what is sold is a dietary supplement authorized by Anvisa only for people over 19, with a warning on the packaging that it should not be consumed by children. None of this is for free use in children: the indication, formulation, and monitoring go through the doctor — and they do not replace sleep hygiene.

verified

Medication doesn't replace interventionThe guidelines' recommendation is consistent: medication is more effective when combined with behavioral and educational strategies, and less effective on its own. A good medication plan has three things in writing: an observable target (“fewer self-injury episodes per week,” not “being calmer”), a way to measure whether it's being reached, and a date to reassess. Without this, there's no way to know whether the medication is helping.

Adverse effects and what gets monitored

Every medication has two sides, and in autism monitoring is especially important — many people have difficulty saying what they're feeling, and an adverse effect can show up as “worsening behavior.” Tap the cards:

warning

Safety firstDo not start, adjust, change, or stop any medication on your own — including over-the-counter ones. The one who prescribes and monitors is the doctor (pediatrician, psychiatrist, or neurologist). If there is immediate risk — severe self-injury, injury, or thoughts of dying or hurting oneself —, seek help right away: in Brazil, CVV, phone 188 (free call, 24 hours) and, in an emergency, SAMU, 192.

What has no support

The absence of a medication for autism has opened the door to a long line of promises. Some have already been tested and failed:

  • Chelation (substances to “remove heavy metals”): the Cochrane review found no evidence of effectiveness and recorded reports of harm — the conclusion is that it should not be recommended.
  • Intravenous secretin: after more than a dozen randomized trials and hundreds of children, no effect. The Cochrane review concludes that it should not be recommended or administered in autism.
  • Exclusion diets (gluten-free or casein-free) for the core symptoms: NICE explicitly recommends against using them for this purpose. Restricting foods without a clinical indication has a real cost for someone who already has food selectivity.
  • Cannabidiol: this is a case of ongoing research, not a ready-made answer. Recent reviews find few randomized trials, small samples, and heterogeneous results, and conclude that the evidence is still insufficient to recommend routine clinical use.

None of these conclusions say “never again”: they say what is known today. That's precisely the difference between treatment and promise — one allows itself to be tested and corrected.

core symptoms co-occurring condition second-generation antipsychotic irritability adjuvant treatment adverse effect

Test your understanding

quiz

Quick quiz

Three questions to reinforce the concept. You'll see the explanation right away.

Further reading

  1. Hyman SL, Levy SE, Myers SM; American Academy of Pediatrics, Council on Children with Disabilities. “Identification, Evaluation, and Management of Children With Autism Spectrum Disorder”. Pediatrics, 2020.
  2. National Institute for Health and Care Excellence (NICE). Autism spectrum disorder in under 19s: support and management (CG170), 2013, with updates.
  3. Hirsch LE, Pringsheim T. “Aripiprazole for autism spectrum disorders (ASD)”. Cochrane Database of Systematic Reviews, 2016.
  4. Williams K, Brignell A, Randall M, Silove N, Hazell P. “Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)”. Cochrane Database of Systematic Reviews, 2013.
  5. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. “Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders With Hyperactivity”. Archives of General Psychiatry, 2005.
  6. Williams K, Wray JA, Wheeler DM. “Intravenous secretin for autism spectrum disorders (ASD)”. Cochrane Database of Systematic Reviews, 2012.
  7. James S, Stevenson SW, Silove N, Williams K. “Chelation for autism spectrum disorder (ASD)”. Cochrane Database of Systematic Reviews, 2015.
  8. European Medicines Agency (EMA). Slenyto (prolonged-release melatonin): product information — European marketing authorization from 2018, for insomnia in children and adolescents with ASD.
  9. Agência Nacional de Vigilância Sanitária (Anvisa). 2021 decision authorizing melatonin as a constituent of dietary supplements, restricted to people over 19.
  10. American Psychiatric Association. DSM-5-TR: Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision, 2022.
info

This entry is educational and does not replace assessment, diagnosis or treatment by a qualified health professional. Every person is unique — for a specific case, seek individual guidance.

Looking for professional guidance?

Instituto Walden4 is a psychology and education center in Brasília, Brazil, offering evidence-based assessment and care for autism, psychotherapy and development — in person and online. Our team serves in Portuguese; get in touch and we will find the best way to help.

chat Message us on WhatsApp
chat

Conta Walden4

Entrar

Use o e-mail e a senha da sua conta.